Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: preventive treatment for patients at risk of COVID-19 infection
ISRCTN88057279Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of sotrovimab, niclosamide and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Oct 2020; status: completed.
02
Drugs
sotrovimabniclosamidehydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN88057279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88057279.